Cargando…

Robust neutralizing antibodies to SARS-CoV-2 infection persist for months

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic with millions infected and more than 1 million fatalities. Questions regarding the robustness, functionality, and longevity of the antibody response to the virus remain unanswered. Here, on the basis of a datas...

Descripción completa

Detalles Bibliográficos
Autores principales: Wajnberg, Ania, Amanat, Fatima, Firpo, Adolfo, Altman, Deena R., Bailey, Mark J., Mansour, Mayce, McMahon, Meagan, Meade, Philip, Mendu, Damodara Rao, Muellers, Kimberly, Stadlbauer, Daniel, Stone, Kimberly, Strohmeier, Shirin, Simon, Viviana, Aberg, Judith, Reich, David L., Krammer, Florian, Cordon-Cardo, Carlos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7810037/
https://www.ncbi.nlm.nih.gov/pubmed/33115920
http://dx.doi.org/10.1126/science.abd7728
_version_ 1783637240815026176
author Wajnberg, Ania
Amanat, Fatima
Firpo, Adolfo
Altman, Deena R.
Bailey, Mark J.
Mansour, Mayce
McMahon, Meagan
Meade, Philip
Mendu, Damodara Rao
Muellers, Kimberly
Stadlbauer, Daniel
Stone, Kimberly
Strohmeier, Shirin
Simon, Viviana
Aberg, Judith
Reich, David L.
Krammer, Florian
Cordon-Cardo, Carlos
author_facet Wajnberg, Ania
Amanat, Fatima
Firpo, Adolfo
Altman, Deena R.
Bailey, Mark J.
Mansour, Mayce
McMahon, Meagan
Meade, Philip
Mendu, Damodara Rao
Muellers, Kimberly
Stadlbauer, Daniel
Stone, Kimberly
Strohmeier, Shirin
Simon, Viviana
Aberg, Judith
Reich, David L.
Krammer, Florian
Cordon-Cardo, Carlos
author_sort Wajnberg, Ania
collection PubMed
description Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic with millions infected and more than 1 million fatalities. Questions regarding the robustness, functionality, and longevity of the antibody response to the virus remain unanswered. Here, on the basis of a dataset of 30,082 individuals screened at Mount Sinai Health System in New York City, we report that the vast majority of infected individuals with mild-to-moderate COVID-19 experience robust immunoglobulin G antibody responses against the viral spike protein. We also show that titers are relatively stable for at least a period of about 5 months and that anti-spike binding titers significantly correlate with neutralization of authentic SARS-CoV-2. Our data suggest that more than 90% of seroconverters make detectable neutralizing antibody responses. These titers remain relatively stable for several months after infection.
format Online
Article
Text
id pubmed-7810037
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher American Association for the Advancement of Science
record_format MEDLINE/PubMed
spelling pubmed-78100372021-01-19 Robust neutralizing antibodies to SARS-CoV-2 infection persist for months Wajnberg, Ania Amanat, Fatima Firpo, Adolfo Altman, Deena R. Bailey, Mark J. Mansour, Mayce McMahon, Meagan Meade, Philip Mendu, Damodara Rao Muellers, Kimberly Stadlbauer, Daniel Stone, Kimberly Strohmeier, Shirin Simon, Viviana Aberg, Judith Reich, David L. Krammer, Florian Cordon-Cardo, Carlos Science Reports Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic with millions infected and more than 1 million fatalities. Questions regarding the robustness, functionality, and longevity of the antibody response to the virus remain unanswered. Here, on the basis of a dataset of 30,082 individuals screened at Mount Sinai Health System in New York City, we report that the vast majority of infected individuals with mild-to-moderate COVID-19 experience robust immunoglobulin G antibody responses against the viral spike protein. We also show that titers are relatively stable for at least a period of about 5 months and that anti-spike binding titers significantly correlate with neutralization of authentic SARS-CoV-2. Our data suggest that more than 90% of seroconverters make detectable neutralizing antibody responses. These titers remain relatively stable for several months after infection. American Association for the Advancement of Science 2020-12-04 2020-10-28 /pmc/articles/PMC7810037/ /pubmed/33115920 http://dx.doi.org/10.1126/science.abd7728 Text en Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works https://creativecommons.org/licenses/by/4.0/ https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution license (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Reports
Wajnberg, Ania
Amanat, Fatima
Firpo, Adolfo
Altman, Deena R.
Bailey, Mark J.
Mansour, Mayce
McMahon, Meagan
Meade, Philip
Mendu, Damodara Rao
Muellers, Kimberly
Stadlbauer, Daniel
Stone, Kimberly
Strohmeier, Shirin
Simon, Viviana
Aberg, Judith
Reich, David L.
Krammer, Florian
Cordon-Cardo, Carlos
Robust neutralizing antibodies to SARS-CoV-2 infection persist for months
title Robust neutralizing antibodies to SARS-CoV-2 infection persist for months
title_full Robust neutralizing antibodies to SARS-CoV-2 infection persist for months
title_fullStr Robust neutralizing antibodies to SARS-CoV-2 infection persist for months
title_full_unstemmed Robust neutralizing antibodies to SARS-CoV-2 infection persist for months
title_short Robust neutralizing antibodies to SARS-CoV-2 infection persist for months
title_sort robust neutralizing antibodies to sars-cov-2 infection persist for months
topic Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7810037/
https://www.ncbi.nlm.nih.gov/pubmed/33115920
http://dx.doi.org/10.1126/science.abd7728
work_keys_str_mv AT wajnbergania robustneutralizingantibodiestosarscov2infectionpersistformonths
AT amanatfatima robustneutralizingantibodiestosarscov2infectionpersistformonths
AT firpoadolfo robustneutralizingantibodiestosarscov2infectionpersistformonths
AT altmandeenar robustneutralizingantibodiestosarscov2infectionpersistformonths
AT baileymarkj robustneutralizingantibodiestosarscov2infectionpersistformonths
AT mansourmayce robustneutralizingantibodiestosarscov2infectionpersistformonths
AT mcmahonmeagan robustneutralizingantibodiestosarscov2infectionpersistformonths
AT meadephilip robustneutralizingantibodiestosarscov2infectionpersistformonths
AT mendudamodararao robustneutralizingantibodiestosarscov2infectionpersistformonths
AT muellerskimberly robustneutralizingantibodiestosarscov2infectionpersistformonths
AT stadlbauerdaniel robustneutralizingantibodiestosarscov2infectionpersistformonths
AT stonekimberly robustneutralizingantibodiestosarscov2infectionpersistformonths
AT strohmeiershirin robustneutralizingantibodiestosarscov2infectionpersistformonths
AT simonviviana robustneutralizingantibodiestosarscov2infectionpersistformonths
AT abergjudith robustneutralizingantibodiestosarscov2infectionpersistformonths
AT reichdavidl robustneutralizingantibodiestosarscov2infectionpersistformonths
AT krammerflorian robustneutralizingantibodiestosarscov2infectionpersistformonths
AT cordoncardocarlos robustneutralizingantibodiestosarscov2infectionpersistformonths